US Patent 7871642 Use of nanodispersions in pharmaceutical end formulations

A nanodispersion comprises(a) a membrane-forming molecule,(b) a coemulsifier and(c) a lipophilic component,in pharmaceutical end formulations, the nanodispersion being obtainable by(α) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and(β) adding the liquid obtained in step (α) to the water phase of the pharmaceutical end formulations, where steps (α) and (β) may be carried out without high energy mixing or homogenization.